ACC
<ѻý class="page-description">American College of Cardiologyѻý>Drug might be most effective with a diuretic, according to suggestive data from a phase II trial
Randomized trial shows better outcomes for patients with acute coronary syndromes
First trial in a quarter-century to show mortality benefit in this desperately ill group
For patients with hypertension, oral device may be an option for those who cannot tolerate CPAP
Patient acceptance could be an advantage, researchers say
Clinical benefit observed years after preventive PCI on non-flow-limiting plaque in PREVENT trial
Nonprescription rosuvastatin pans out in a second trial
Researcher suggests findings are robust enough to change practice guidelines
After ORBITA-COSMIC, Reducer device's mechanism of benefit remains unknown
HDL therapeutic failed to reduce risk of MI, stroke, or cardiovascular death in high-risk group
TACT2 trial fails to confirm benefits in subgroup that gained the most in initial trial
Standard medications losing appeal amid more modern heart attack treatments
Two trials show promise in moderate and extreme elevations
Two common devices go head to head in people with small aortic annuli
-
AHA: American Heart Association
November 2024
-
TCT: Transcatheter Cardiovascular Therapeutics
October 2024
-
HFSA: Heart Failure Society of America
September 2024
-
ESC: European Society of Cardiology Congress
August 2024